drugset
drugset / Trial / NCT07417735

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

NCT07417735 ↗

Phase 3 Not yet recruiting 436 enrolled CSPC Megalith Biopharmaceutical Co.,Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line of Systemic Therapy

Timeline

Start
2026-03-18
Primary completion
2028-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Docetaxel Small molecule 75 mg/m2 Intravenous
Comparator Docetaxel Small molecule 100 mg/m2 Intravenous
Comparator Irinotecan Small molecule 125 mg/m2 Intravenous
Comparator Irinotecan Small molecule 150 mg/m2 Intravenous
Comparator Irinotecan Small molecule 180 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 80 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 175 mg/m2 Intravenous
Subject SYS6010 Monoclonal antibody — Intravenous

Indications

esophageal squamous cell carcinoma